background
current
viru
discoveri
mainli
base
molecular
techniqu
propos
method
reli
viru
cultur
combin
stateoftheart
sequenc
techniqu
natur
ex
vivo
cultur
system
use
enabl
replic
respiratori
virus
method
three
respiratori
clinic
sampl
test
welldifferenti
pseudostratifi
tracheobronchi
human
airway
epitheli
hae
cultur
grown
airliquid
interfac
resembl
airway
epithelium
cell
stain
convalesc
serum
patient
identifi
infect
cell
apic
wash
analyz
nextgener
sequenc
viru
discoveri
techniqu
result
infect
cell
observ
three
sampl
sequenc
subsequ
indic
cell
infect
either
human
coronaviru
influenzaviru
b
influenzaviru
sequenc
read
cover
larg
part
genom
respect
conclus
present
new
method
viru
discoveri
requir
viru
cultur
primari
cell
antibodi
detect
viru
harvest
use
character
viral
genom
sequenc
cell
tropism
also
provid
progeni
viru
initi
experi
fulfil
koch
postul
discoveri
new
virus
boost
last
decad
highthroughput
sequenc
method
techniqu
gener
ten
thousand
sequenc
read
directli
clinic
sampl
sequenc
align
tool
subsequ
reveal
presenc
previous
unknown
virus
main
limit
viral
metagenom
techniqu
detect
sequenc
read
deriv
viral
genom
necessarili
indic
viru
pathogen
absenc
inform
phenotyp
properti
infect
cell
tropism
abil
induc
immun
system
new
viru
identifi
fulfil
koch
postul
need
establish
role
viru
diseas
viru
cultur
stage
thu
need
obtain
rel
pure
viru
stock
inocul
anim
model
viru
cultur
remain
major
bottleneck
centuri
viru
research
identif
larg
part
limit
agent
could
cultur
convent
cell
line
recent
power
sequenc
method
allow
identif
new
virus
clinic
sampl
viru
cultur
amplif
step
longer
requir
downsid
without
viru
cultur
possibl
formal
fulfil
koch
postul
result
one
describ
diseas
associ
either
higher
viral
preval
infect
subject
compar
control
seroconvers
agent
cours
follow
diseas
welldifferenti
pseudostratifi
airway
epithelium
form
cultur
primari
human
airway
epitheli
cell
hae
airliquid
interfac
morpholog
function
cell
resembl
human
airway
system
use
cultur
wide
rang
respiratori
virus
exampl
influenzaviru
parainfluenza
viru
respiratori
syncyti
viru
adenoviru
sever
acut
respiratori
syndrom
coronaviru
furthermor
virus
recent
describ
cultur
cell
wherea
regular
cell
line
permiss
result
collect
suggest
hae
cultur
promis
tool
univers
respiratori
viru
discoveri
combin
power
techniqu
viru
hae
cultur
viru
isol
nextgener
sequenc
detect
viral
genom
might
ideal
futur
viru
discoveri
program
howev
one
pitfal
hae
cultur
even
fast
replic
respiratori
viru
cytopath
effect
rare
observ
influenzaviru
strain
caus
cell
death
major
infect
chang
epitheli
layer
thu
hae
combin
viru
detect
propos
immunostain
convalesc
serum
collect
patient
obtain
week
respiratori
infect
serum
like
contain
substanti
antibodi
titer
viru
caus
respiratori
ill
week
earlier
proof
principl
studi
test
combin
replic
unknown
respiratori
viru
hae
cell
cultur
follow
immunostain
patient
serum
unbias
detect
infect
viru
metagenom
viru
discoveri
tool
viru
discoveri
cdnaaflp
combin
roch
highthroughput
sequenc
latter
amplif
techniqu
develop
laboratori
allow
sequenc
rna
dna
virus
independ
genom
sequenc
three
respiratori
samplesanonym
respect
infect
agent
determin
routin
diagnosticswer
includ
studi
three
case
viru
could
cultur
detect
patient
antibodi
identifi
three
respiratori
sampl
copan
nasal
swab
univers
transport
medium
collect
patient
lower
respiratori
tract
ill
via
grace
european
network
excel
test
blindli
sampl
collect
patient
bialystock
poland
lodz
poland
mataro
spain
serum
collect
week
acut
phase
lower
respiratori
tract
ill
patient
normal
primari
human
bronchial
epitheli
cell
hbepc
isol
patient
year
old
underw
bronchoscopi
andor
surgic
lung
resect
diagnost
pathway
pulmonari
diseas
carri
accord
local
regul
academ
medic
center
netherland
patholog
examin
bronchial
segment
incub
hour
minim
essenti
medium
mem
sigma
st
loui
mo
usa
supplement
mixtur
proteas
xivdnas
sigma
follow
addit
sigma
penicillin
g
sulfat
unitsml
streptomycin
sulfat
lgml
amphotericin
b
lgml
gentamicin
lgml
nystatin
unitsml
cell
dissoci
hbepc
maintain
monolay
bronchial
epitheli
cell
serumfre
growth
medium
begm
lhc
basal
medium
invitrogen
carlsbad
ca
usa
supplement
requir
addit
describ
fulcher
et
al
begm
refresh
interv
reach
confluenc
cell
dissoci
ml
trypl
express
enzym
invitrogen
dilut
airliquid
interfac
medium
mixtur
lhc
basal
medium
invitrogen
dulbecco
modifi
eagl
medium
invitrogen
supplement
requir
addit
sigma
total
cell
seed
type
iv
collagen
sigma
coat
thincert
pore
size
greiner
bioon
frickenhausen
germani
medium
renew
everi
day
cultur
reach
full
confluenc
cell
expos
air
cultur
airliquid
interfac
maintain
deepwel
plate
greiner
bioon
day
let
cell
differenti
pseudostratifi
human
airway
epitheli
cell
cultur
medium
basolater
compart
renew
everi
day
apic
surfac
wash
everi
day
hank
balanc
salt
solut
hbss
invitrogen
prior
experi
cultur
maintain
co
incub
prior
infect
apic
surfac
hae
cell
rins
three
time
hbss
inocul
apic
surfac
respiratori
sampl
follow
hour
incub
co
incub
unbound
viru
remov
rins
apic
surfac
hbss
min
hae
maintain
airliquid
interfac
remaind
experi
harvest
collect
hour
postinocul
apic
basolater
side
except
sampl
last
harvest
collect
hour
postinocul
apic
wash
harvest
perform
ad
hbss
apic
surfac
incub
minut
co
incub
follow
remov
storag
hbss
apic
surfac
ninetysix
hour
postinfect
cultur
use
immunostain
timepoint
chosen
sure
abl
detect
infect
cell
even
virus
replic
slower
averag
respiratori
virus
averag
peak
hour
postinfect
apic
basolater
side
rins
phosphatebuff
salin
pb
follow
fixat
freshli
prepar
paraformaldehyd
pfa
formafix
minut
room
temperatur
apic
basolater
side
subsequ
wash
three
time
pb
confoc
stain
buffer
pb
supplement
mm
nh
cl
saponin
bsa
iggfre
ad
side
subsequ
wash
confoc
stain
buffer
cell
incub
apic
side
autolog
convalesc
serum
patient
dilut
confoc
stain
buffer
mous
monoclon
antibtubulin
iv
sigma
minut
room
temperatur
cell
subsequ
wash
confoc
stain
buffer
follow
incub
donkeyderiv
dylight
antimous
igg
hl
dylight
antihuman
igg
hl
dilut
confoc
stain
buffer
jackson
immunoresearch
hour
rt
cell
wash
confoc
stain
buffer
final
pb
remov
saponin
filter
cell
subsequ
excis
insert
place
glass
slide
mount
medium
molecular
probe
apic
side
upward
mount
medium
coverslip
ad
top
fluoresc
imag
acquir
use
leica
tc
aob
spectral
confoc
microscop
wetzlar
germani
imag
captur
analysi
process
perform
use
leica
applic
suit
advanc
fluoresc
lite
softwar
packag
leica
perform
previous
describ
short
viru
harvest
centrifug
min
g
supernat
treat
turbo
dnase
ull
ambion
austin
tx
usa
subsequ
nucleic
acid
extract
boom
method
rrnablock
oligonucleotid
ad
prevent
amplif
ribosom
rna
revers
transcript
reaction
superscript
ii
invitrogen
perform
use
nonribosom
random
hexam
primer
mid
ribosom
rna
sequenc
trim
remov
sequenc
read
sequenc
assembl
codoncod
align
softwar
codoncod
corpor
centervil
usa
version
contig
sequenc
unassembl
read
compar
avail
sequenc
genbank
via
blastn
tool
use
default
set
blast
output
use
creat
taxonom
classif
read
megan
softwar
version
univers
germani
follow
set
use
min
support
min
score
min
scorelength
top
percent
full
recoveri
patient
appar
theori
sera
contain
substanti
amount
pathogenspecif
immunoglobulin
recogn
epitop
expos
viru
surfac
addit
cell
stain
monoclon
antibodi
ciliat
cellspecif
marker
iv
identifi
ciliat
cell
three
cultur
infect
cell
could
visual
confoc
microscopi
figur
sampl
stain
infect
ciliat
cell
visibl
wherea
sampl
show
stain
ciliat
noncili
cell
furthermor
strong
cytopath
effect
note
detach
cell
filter
cell
debri
apic
wash
apic
wash
obtain
hour
postinocul
use
input
viru
discoveri
three
cultur
harvest
total
sequenc
read
obtain
ident
search
use
blast
tool
ncbi
show
sampl
contain
differ
respiratori
viru
human
coronaviru
sampl
influenzaviru
sampl
influenzaviru
b
sampl
number
read
substanti
viru
case
total
read
importantli
larg
coverag
genom
obtain
virus
see
supplementari
data
remark
thousand
sequenc
obtain
per
sampl
tabl
replic
influenzaviru
b
hae
noteworthi
knowledg
first
descript
spread
infect
caus
viru
hae
therefor
determin
replic
characterist
quantif
viral
rna
apic
harvest
figur
viru
product
detect
earli
hour
postinfect
maximum
hour
postinfect
current
avail
highthroughput
sequenc
platform
gener
impress
amount
sequenc
inform
short
time
frame
acquisit
essenti
addit
knowledg
need
address
pathogen
novel
viru
lag
behind
discoveri
novel
human
viru
prefer
accompani
serolog
seroconvers
viru
acut
convalesc
phase
diseas
associ
diseas
frequent
detect
diseas
case
compar
healthi
control
ideal
viru
cultur
system
first
requir
fulfil
koch
postul
studi
present
combin
viru
cultur
method
viru
discoveri
tool
allow
identif
respiratori
virus
elicit
immun
respons
abl
infect
cell
match
affect
organ
clinic
specimen
origin
obtain
three
clinic
sampl
use
evalu
combin
culturevirusdiscoveri
tool
three
virus
stain
infect
hae
cell
convalesc
serum
patient
posit
apic
wash
investig
sequenceindepend
viru
discoveri
tool
detect
rna
dna
virus
sequenc
read
provid
high
genom
coverag
provid
opportun
identifi
virus
highli
diverg
known
virus
inclus
conserv
domain
like
apic
wash
thousand
sequenc
read
suffici
low
number
read
need
identifi
cultur
viru
advantag
mani
sampl
analyz
parallel
singl
run
approxim
sampl
per
run
make
assay
moder
expens
one
note
howev
combin
assay
current
suitabl
use
highthroughput
set
signific
handson
time
expert
experi
need
prepar
hae
cell
cultur
hand
avail
cultur
method
enorm
benefici
followup
studi
provid
progeni
viru
materi
exampl
inocul
anim
fulfil
postul
koch
document
replic
three
respiratori
virus
respiratori
tract
cell
equal
relev
use
equival
combin
system
discoveri
pathogen
gastrointestin
virus
fecal
sampl
contain
whole
rang
nonrelev
virusesmani
still
unknownthat
either
origin
food
collect
phage
infect
intestin
bacteria
advanc
intestin
epitheli
cultur
system
develop
human
intestin
organoid
system
promis
viru
replic
could
combin
stain
viru
discoveri
identifi
virus
infect
human
cell
intestin
recent
publish
viru
discoveri
tool
reli
antibodi
captur
therebi
circumv
problem
foodrel
virus
mistaken
human
pathogen
ad
viru
cultur
step
would
add
even
weight
discoveri
bacteriophag
foodinfect
virus
incap
infect
intestin
epitheli
cell
addit
advantag
immunostain
identifi
virusposit
cultur
cell
tropism
viru
determin
time
observ
infect
ciliat
cell
infect
ciliat
noncili
cell
influenzaviru
infect
accord
literatur
influenzaviru
b
replic
ciliat
noncili
cell
describ
previous
human
influenzaviru
b
ha
protein
structur
similar
preferenti
bind
link
sialic
acid
accord
cell
tropism
virus
choic
welldifferenti
pseudostratifi
human
airway
epitheli
cell
base
inhous
experi
major
respiratori
virus
replic
cultur
even
one
cultur
tradit
cell
line
eg
human
bocaviru
human
coronaviru
procedur
cultur
differenti
cell
describ
detail
handl
cell
requir
technic
experi
rel
much
handson
time
therefor
routin
avail
laboratori
altern
may
obtain
hae
commerci
supplier
eg
human
upper
airway
epithelia
mucilair
tm
epithelix
geneva
switzerland
compar
cultur
perform
neg
stain
control
infect
cell
leav
convalesc
serum
check
whether
procedur
would
give
falseposit
perform
control
howev
studi
stain
infect
uninfect
cell
distinct
neg
primari
antibodi
ad
anoth
control
infect
cell
incub
convalesc
serum
also
includ
control
howev
need
viru
discoveri
ultim
identif
viru
via
sequenc
read
falseposit
stain
result
falseposit
viru
identif
discoveri
method
may
work
stain
convalesc
serum
yield
signal
occur
igm
iga
igg
yet
secondari
antibodi
recogn
igg
respons
infect
occur
mucosa
via
iga
latter
issu
could
theoret
address
later
respiratori
sampl
avail
materi
subsequ
use
sourc
primari
antibodi
one
limit
combin
discoveri
tool
patient
studi
collect
convalesc
serum
infect
case
materi
lack
possibl
use
concentr
immunoglobulin
multipl
donor
ivig
nanogam
sanquin
bv
pool
abl
detect
virus
common
popul
yet
discov
case
rhinoviru
c
human
bocaviru
etc
pool
immunoglobulin
could
also
recogn
emerg
virus
like
sarscov
andor
merscov
shown
antibodi
direct
common
cold
coronavirus
may
display
crossreact
newli
emerg
coronavirus
conclus
present
combin
viru
discoveri
approach
exclus
identifi
virus
infect
human
cell
elicit
immun
respons
strong
indic
identifi
agent
caus
agent
diseas
addit
support
inform
may
found
onlin
version
articl
figur
supplimentari
influenza
influenza
b
align
